The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Efficacy of cetuximab immediately after bevacizumab: A phase III multicenter trial comparing two different sequences of cetuximab and FOLFOX in K-Ras WT metastatic colorectal cancer patients refractory FOLFIRI/bevacizumab.
 
Stefano Cascinu
Consulting or Advisory Role - Merck Serono; Roche/Genentech
Research Funding - Merck Serono; Roche/Genentech
 
Alberto Zaniboni
Consulting or Advisory Role - Merck; Roche/Genentech
 
Sara Lonardi
Honoraria - Merck Serono; Roche/Genentech
 
Gerardo Rosati
No Relationships to Disclose
 
Guglielmo Nasti
No Relationships to Disclose
 
Monica Giordano
No Relationships to Disclose
 
Domenico C. Corsi
No Relationships to Disclose
 
Francesco Ferraú
Honoraria - Roche/Genentech
Travel, Accommodations, Expenses - Merck Serono
 
Rosario Vincenz Iaffaioli
Travel, Accommodations, Expenses - Roche/Genentech
 
Paolo Marchetti
Honoraria - Roche
Consulting or Advisory Role - Roche/Genentech
 
Massimo Aglietta
Honoraria - Roche/Genentech
Travel, Accommodations, Expenses - Roche/Genentech
 
Domenico Bilancia
No Relationships to Disclose
 
Monica Ronzoni
No Relationships to Disclose
 
Irene Claudia Floriani
No Relationships to Disclose
 
Roberto Labianca
Honoraria - Merck; Roche/Genentech
Consulting or Advisory Role - Merck Serono; Roche/Genentech
Research Funding - Roche/Genentech
Travel, Accommodations, Expenses - Merck Serono; Roche/Genentech